2019 SFU Beedie i2i Venture Pitch Competition

Oct 23, 2019 05:30 PM to 09:00 PM

Registration Deadline: Oct 23, 2019 05:30 PM

Wednesday, October 23, 2019
 

Register today to attend the 2019 SFU 'Invention to Innovation' Venture Pitch Competition. At this event, three scientist-entrepreneurship students of the Invention to Innovation program will pitch their product-ready ventures and three more will pitch their emergent ventures to our panel of expert judges.


Event Details

Date:
Wednesday, October 23, 2019
Time:
5:30pm - 9:00pm
Location:
Segal Graduate School of Business
500 Granville Street, Vancouver, BC
Registration:
Attendance is complimentary, but registration is required. Please reserve your spot by registering here.

Your first drink is on us and a selection of canapes will be provided. A cash bar will also be available
Inquiries:

Judges

 

Norma Biln: Co-Founder and Chief Executive Officer, Augurex Life Sciences Corp

Norma Biln was recently recognized as one of Canada's Most Powerful Women: Top 100 Award Winner in 2017, and BC's Most Influential Women 2018: STEM Stars. Throughout her 24 years in the life sciences she has worked along, built and led teams that have consistently exceeded corporate goals. Norma began her career in clinical research with Pfizer Pharmaceuticals after completing her Bachelor of Science in Physiology at McGill University.

She continued her career in several capacities in sales management, marketing and market access with Pfizer Pharmaceuticals, Amgen and Abbott Laboratories. Before her role of CEO at Augurex, Norma worked in various senior management roles in Business Development, Commercial and Communications. She holds a Master of Business Administration and is pursuing her Doctorate, part-time at UBC's School of Population and Public Health. Norma is a member of the Board of Directors of Resverlogix Corp (TSX:RVX), BIOTECanada, the national industry association and New Ventures BC, the province's premiere tech competition and early-stage accelerator.
 

David Granville, PhD, FAHA: Professor, Pathology and Laboratory Medicine, University of British Columbia
Associate Director, Vancouver Coastal Health Research Institute
Associate Director, BC Professional Firefighters' Burn and Wound Healing Group, UBC
Principal Investigator, International Collaboration On Repair Discoveries (iCORD)
Principal Investigator, UBC Centre for Heart Lung Innovation
Associate Member, Division of Plastic Surgery, Department of Surgery, UBC
Founder and Chief Scientific Officer, viDA Therapeutics Inc.

Dr. Granville is a Full Professor in Pathology and Laboratory Medicine, UBC and the Associate Director of the Vancouver Coastal Health Research Institute. Previously, he worked at QLT Inc. (1994-2001) where his research supported the development and approval of Visudyne® as the first treatment for age-related macular degeneration, the leading cause of blindness in the elderly. In 1999 Visudyne® was approved by the FDA resulting in the largest ophthalmic product release in history. His research is referred to on the drug label for Visudyne® and he is listed as a primary inventor on several patents pertaining to this work. In 2001, his work at the Scripps Research Institute (La Jolla, CA) identified a novel therapeutic approach for reducing ischemic damage to the heart. He is a primary inventor on patents pertaining to the latter discoveries that led to the formation of Radical Therapeutix Inc (San Diego, CA). In 2003 Dr. Granville was recruited back to UBC as a Canada Research Chair and Michael Smith Foundation for Health Research Scholar. He has received awards including: Canada Top 40 Under 40™ award, UBC Outstanding Young Alumnus Award, SFU Academic Alumnus Award, Business in Vancouver Top Forty Under 40 Award. He is also a Fellow of the American Heart Association (FAHA) and a Scholar of the Royal Society of Canada. Since arriving at UBC, his research has resulted in the filing of 32 patents. He is also a co-Founder and serves as the Chief Scientific Officer of viDA Therapeutics, Inc.
 

Maria Pacella, CFA: Senior VP, Private Equity and Portfolio Manager, Pender Fund Capital Management

Maria Pacella joined Pender in January 2017. She has been investing in emerging growth companies, with a focus on technology businesses since 2001. She spent 11 years with one of Canada's largest venture capital firms where she invested in multiple early-stage ventures and served on a variety of boards, mostly in the areas of enterprise software, e-commerce and med-tech. Prior to that she worked at a digital media firm assisting the company in operational activities and strategic initiatives.

She also worked in financial and technology M & A for the Canadian subsidiary of an international investment firm. Maria's experience includes operational roles at early‐stage companies, serving on boards, facilitating M & A's and leading financings. She has built an extensive technology network across North America, notably in Silicon Valley, and has been a member of C100. She is currently a director on the board of Clarius Mobile Health, Jane Software, Teradici and BasicGov and an observer on the board of Tantalus Systems. She is also on the SFU Beedie School of Business Advisory Board.She holds a BBA from Simon Fraser University, is a CFA charterholder and an active member and a past President of CFA Society Vancouver. As an investor in the rapidly changing world of early stage technology, Maria invests in exceptional entrepreneurs and teams that excel at identifying business opportunities, develop world-class products and are dedicated to building great companies.
 

Mark Longo: Managing Partner, Osler, Hoskin & Harcourt LLP

Mark Longo is Managing Partner of the law firm Osler, Hoskin & Harcourt's Vancouver office and Co-Chair of Osler's Emerging & High Growth Companies Group. Mark has 25 years' experience in venture finance, mergers & acquisitions and technology law and previously held general counsel and executive positions for private and public technology companies. Mark is ranked as a leading corporate lawyer by Lexpert and Chambers. Mark obtained his BA from McGill University, his Bachelor of Laws from Queen's University and his MBA from the Ivey School of Business at the University of Western Ontario. Mark is called to the Bar in British Columbia and Ontario.

Joshua Zoshi: Co-founder and Chief Operating Officer, Saltworks Technologies

Joshus Zoshi has helped grow Saltworks into a leading provider of innovative water treatment solutions for mining, oil & gas, aerospace, and other industries. His background spans semiconductors, energy, and enterprise software. He received his Bachelor of Applied Science in Electrical Engineering and his Master of Business Administration (Management of Technology) both from Simon Fraser University. He has a relentless curiosity about technology, business challenges, and nature - especially our oceans. Josh lives with his wife in Vancouver and can usually be found snowboarding the local hills, trying the cit's food trucks, and taking every opportunity to scuba dive in exotic locations.


Venture Pitches

Evan Macdonald, Roam Health
Roam Health makes Stryde, a low-cost, easy to use smart shoe insole that analyzes the wearer's activities and provides feedback about specific behaviours and recommended modifications to prevent foot pain and lower body injuries.

Jaeyong Lee, Protemer Inc.
Protemer develops and supplies novel protein-based hydrogel that can serve as a biocompatible platform for growing human cells in biomedical and pharmaceutical research.

Sasan V. Grayli, IE-9 Technology Corp.
IE-9's innovative technology provides enhanced security and anti-counterfeiting capabilities by uniting both visual and machine-readable security components into one optical variable device (OVD).

Steven Hallam, Koonkie Inc.
Koonkie shortens the path to data-driven discovery and innovation using machine learning algorithms and scalable software tools in the cloud, integrating a wide range of physical, chemical, and biological measurements with genomic sequence information to optimize product development and improve process controls across industrial and health care sectors.

Viridiana Perez, Detexi Diminuta
Detexi Diminuta is an early stage venture dedicated to commercializing portable detection kits for nanomaterials to prevent occupational exposure and protect workers health.

Thiago Gasperini Bassi, Ideal
Drawing on neuroscience, Ideal is developing machine-brain interface and digital gaming solutions for stroke rehabilitation.


About the Invention to Innovation (i2I) program

This innovative program has empowered two cohorts of PhD, post-doctoral fellows, and researchers to become scientists-entrepreneurs through business skills development. With that business knowledge, scientists can be more involved in the commercialization of their inventions, which in turn will see more innovative technology making it out of the lab and into the market place.

"Our goal with the Invention to Innovation program is to help Canada's world leading scientists and engineers get the perspective they need to lead innovation throughout their careers," says Elicia Maine, academic director of the Graduate Certificate in Science and Technology Commercialization. "This will be a huge advantage to them and to our economy, as these scientist-entrepreneurs will understand the importance of early stage market assessment, be more comfortable managing under uncertainty, and will be able to lead New Product Development, either within their own venture or for an existing firm."

"The program really clarified what it was to have a business plan and what it meant to attract investors and actually sell the value of your product in non-technical terms," says Ben Britton, CEO of Ionomr and winner of the 2016 Product Ready Venture Pitch competition. "Before, I would talk about the engineering side or the theoretical side, but that's not what they mean. They want to know why this is worth investing in and how much money it could potentially make."

Sponsored by
 

SFU Beedie School of Business
500 Granville Street
Vancouver, BC. V6C 1W6

No spaces remaining or registration is closed.